Home THERAPY AREAS Establishing 25(OH)D-level adequacy in patients with ND-CKD 18 February 2022 Nephrology and Rare Diseases CKD-MBD and SHPT In the final part of this presentation, Dr. Jan Kielstein and Prof. James Wetmore came together to discuss why they support the new target 25(OH)D level for patients with ND-CKD (>50 ng/mL [>124.8 nmol/L]), including justifications such as improved control of key biochemical parameters (levels of PTH, calcium, and phosphorus) in patients with SHPT. The experts also reviewed the current clinical guidelines and explored how ND-CKD patient management and outcomes can be enhanced using novel therapeutics.